In this week's video, Dr. Brian Durie discusses what patients and caregivers need to know on the recent approval of elotuzumab (Empliciti).

Bottom Line:

Empliciti is a useful drug when used in combination with Rev/dex in a relapse setting.

Previous Post
The Black Swan Research Initiative Is the “Myeloma Moonshot”
Next Post
To collaborate, or not to collaborate, that is the question

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.